This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Evogliptin
DrugBank Accession Number
DB12625
Background

Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 401.43
Monoisotopic: 401.192626198
Chemical Formula
C19H26F3N3O3
Synonyms
  • Evogliptin
External IDs
  • DA-1229

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Evogliptin.
AcebutololThe therapeutic efficacy of Evogliptin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Evogliptin can be increased when used in combination with Acetazolamide.
AcetohexamideEvogliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Evogliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Evogliptin.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Evogliptin.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Evogliptin.
AlogliptinThe risk or severity of angioedema can be increased when Alogliptin is combined with Evogliptin.
AlteplaseThe risk or severity of angioedema can be increased when Alteplase is combined with Evogliptin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
A10BH07 — EvogliptinA10BD22 — Metformin and evogliptin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Hybrid peptides
Direct Parent
Hybrid peptides
Alternative Parents
Beta amino acids and derivatives / Alpha amino acids and derivatives / Amphetamines and derivatives / Aralkylamines / Fluorobenzenes / Piperazines / Aryl fluorides / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Lactams
show 8 more
Substituents
1,4-diazinane / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Amphetamine or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
09118300L7
CAS number
1222102-29-5
InChI Key
LCDDAGSJHKEABN-MLGOLLRUSA-N
InChI
InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
IUPAC Name
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(tert-butoxy)methyl]piperazin-2-one
SMILES
CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F

References

General References
Not Available
PubChem Compound
25022354
PubChem Substance
347828837
ChemSpider
26339341
BindingDB
50344779
ChEMBL
CHEMBL1779710
ZINC
ZINC000068267685
PDBe Ligand
8VU
Wikipedia
Evogliptin
PDB Entries
5y7k

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentFibrosis, Liver / Hepatitis B Chronic Infection / Type 2 Diabetes Mellitus1
4CompletedTreatmentFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD / Type 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus1
4Not Yet RecruitingPreventionCAVD1
4Not Yet RecruitingTreatmentDiabetes Mellitus / Endocrine System Diseases / Kidney Diseases / Metabolic Diseases / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentMetabolic Bone Disorder / Type 2 Diabetes Mellitus1
4RecruitingTreatmentChronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes1
4Unknown StatusTreatmentOsteoporosis / Type 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus4
2Active Not RecruitingPreventionCalcific Aortic Valve Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP1.29ALOGPS
logP1.17Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)13.69Chemaxon
pKa (Strongest Basic)8.78Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area84.66 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity97.43 m3·mol-1Chemaxon
Polarizability39.21 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 23:18 / Updated at February 21, 2021 18:53